TCRR - TCR2 Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-35.62M

Cash

110.3M

Avg Qtr Burn

-27.58M

Short % of Float

1.16%

Insider Ownership

1.50%

Institutional Own.

54.32%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Gavo-cel (TC-210) (Mesothelin) Details Solid tumor/s, Mesothelin-expressing solid tumors, Ovarian cancer, Non-small cell lung carcinoma, Cholangiocarcinoma, Malignant pleural/peritoneal mesothelioma, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TC-510 Details Cancer, Ovarian cancer, Colorectal cancer , Pancreatic cancer, Mesothelioma, Triple-negative breast cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TC-110 (CD19) Details Non-Hodgkin lymphoma, Leukemia, Acute lymphoblastic leukemia, Diffuse large B cell lymphoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.